Search clinical trials for: AR9281

Total 38 results

Astex Pharmaceuticals, Inc.

Terminated

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

United States
NCIC Clinical Trials Group
Astex Pharmaceuticals, Inc.

Completed

A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Canada
Istituto Auxologico Italiano
University of Florence; Apnimed Inc.; VIS Ethic Research Srl; STM Pharma PRO srl

Recruiting

Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome (ATOHS)

Obesity Hypoventilation Syndrome (OHS)

Italy
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours

Advanced Solid Tumours
Arcus Biosciences, Inc.
Gilead Sciences

Completed

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

Healthy Participants

United States
Cancer Research UK

Completed

AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia

Leukemia

United Kingdom
NCIC Clinical Trials Group
Astex Pharmaceuticals, Inc.

Completed

Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

Unspecified Adult Solid Tumor, Protocol Specific | Non-Hodgkins Lymphoma

Canada
Ambrx, Inc.
Merck Serono International SA

Completed

Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

Growth Hormone Deficiency

Hungary
Arete Therapeutics

Completed

Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

Hypertension | Impaired Glucose Tolerance

United States
Arcus Biosciences, Inc.
Gilead Sciences

Completed

A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer

Healthy Participants

Netherlands
Aimmune Therapeutics, Inc.

Terminated

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Hen Egg Allergy

United States
National Cancer Institute (NCI)

Completed

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Breast Cancer | Ovarian Cancer

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Arcus Biosciences, Inc.

Completed

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Melanoma | Renal Cell Carcinoma | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Castration-resistant Prostate Cancer | Merkel Cell Carcinoma | GastroEsophageal Cancer

United States, Australia
Arcus Biosciences, Inc.

Completed

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Colorectal Cancer | GastroEsophageal Cancer

United States, Australia
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Singapore, Hong Kong, Canada
Cancer Research UK

Completed

AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United Kingdom
Surface Oncology
Arcus Biosciences, Inc.

Completed

Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Jennifer Choe
Arcus Biosciences, Inc.

Withdrawn

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN)

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Oropharynx Cancer | Oral Cavity Cancer | Oropharynx Squamous Cell Carcinoma | Pharynx Cancer | Larynx Cancer | Hypopharynx Cancer | Oral Cavity Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma

United States
Weill Medical College of Cornell University
Arcus Biosciences, Inc.

Recruiting

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. (PANTHER)

Rectal Cancer

United States
Olive Lifesciences Pvt Ltd

Completed

Safety and Efficacy Study of Herbal Supplements in Prediabetic and Mild to Moderate Hyperlipidemic Patients

Hyperlipidemia | Prediabetes

India
University College, London
AstraZeneca

Withdrawn

Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (ORCA)

Carcinoma, Squamous Cell
Taizhou Hospital

Not yet recruiting

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Lung Cancer, Nonsmall Cell
Fudan University

Not yet recruiting

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

Brain Metastasis | TNBC

China
Fudan University

Recruiting

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Advanced Salivary Gland Carcinoma

China
Catherine Spina
Arcus Biosciences, Inc.

Recruiting

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer (SBRT-AMICO)

Oligometastatic Prostate Cancer

United States
Hoffmann-La Roche

Terminated

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Colorectal Cancer

United States, Korea, Republic of, Australia, France, Switzerland
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (ARC-4)

Non Small Cell Lung Cancer | Nonsquamous Nonsmall Cell Neoplasm of Lung | Non Small Cell Lung Cancer Metastatic | Sensitizing EGFR Gene Mutation

United States, Korea, Republic of, Singapore, Taiwan
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (ARC-9)

Metastatic Colorectal Cancer

Spain, United States, Korea, Republic of, France, United Kingdom, Italy
Gulam Manji
Arcus Biosciences, Inc.

Recruiting

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (AIRPanc)

Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center

Recruiting

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Metastatic Cancer | Urothelial Carcinoma

United States
Lawrence Fong
Genentech, Inc.

Recruiting

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Prostate Cancer | Prostate Adenocarcinoma | Localized Prostate Cancer

United States
University of Maryland, Baltimore
Bill and Melinda Gates Foundation

Completed

Maternal Flu Vaccine Trial in Bamako, Mali

Influenza

Mali
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)

Prostatic Neoplasms, Castration-Resistant | Prostatic Cancer, Castration-Resistant | Castration Resistant Prostatic Neoplasms | Androgen-Resistant Prostatic Neoplasms

United States, Canada
Arcus Biosciences, Inc.
Infinity Pharmaceuticals, Inc.

Completed

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Ovarian Cancer | TNBC - Triple-Negative Breast Cancer

United States, Australia
Arcus Biosciences, Inc.

Completed

A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants

Healthy Participants

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Pancreatic Adenocarcinoma

United States, Spain, Korea, Republic of, Germany, Japan
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom

Search clinical trials for: AR9281

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations